NanoRepro AG (FRA:NN6)

Market Cap	22.70M +33.8%
Revenue (ttm)	5.17M +45.0%
Net Income	-1.72M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,620
Open	1.815
Previous Close	1.800
Day's Range	1.750 - 1.815
52-Week Range	1.310 - 2.100
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 5, 2026

About NanoRepro AG

NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. It offers rapid diagnostic tests, such as family planning, and preventive healthcare line products. The company also develops and commercializes immunochromatographic lateral flow tests; and tests for hospitals and medi...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2006
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NN6

Financial Performance

In 2024, NanoRepro AG's revenue was 4.51 million, an increase of 41.68% compared to the previous year's 3.18 million. Losses were -2.05 million, -56.34% less than in 2023.